Rao YY, Zhang HJ, Wang XJ, Li MF. Primary hepatic neuroendocrine tumor — 18F-fluorodeoxyglucose positron emission tomography/computed tomography findings: A case report. World J Clin Cases 2021; 9(22): 6450-6456 [PMID: 34435011 DOI: 10.12998/wjcc.v9.i22.6450]
Corresponding Author of This Article
Yan-Ying Rao, MD, Attending Doctor, Department of Radiology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, No. 420 Fuma Road, Jin'an District, Fuzhou 350000, Fujian Province, China. yanying.rao@fjzlhospital.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2021; 9(22): 6450-6456 Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6450
Primary hepatic neuroendocrine tumor — 18F-fluorodeoxyglucose positron emission tomography/computed tomography findings: A case report
Yan-Ying Rao, He-Jun Zhang, Xiao-Jiang Wang, Min-Feng Li
Yan-Ying Rao, Min-Feng Li, Department of Radiology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou 350000, Fujian Province, China
He-Jun Zhang, Xiao-Jiang Wang, Department of Pathology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou 350000, Fujian Province, China
Author contributions: Rao YY proposed the study and wrote the first draft; Wang XJ, Zhang HJ and Li MF analyzed the data; all authors contributed to the design and interpretation of the study and to the preparation of further drafts.
Informed consent statement: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Ying Rao, MD, Attending Doctor, Department of Radiology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, No. 420 Fuma Road, Jin'an District, Fuzhou 350000, Fujian Province, China. yanying.rao@fjzlhospital.com
Received: March 21, 2021 Peer-review started: March 21, 2021 First decision: April 29, 2021 Revised: May 11, 2021 Accepted: June 1, 2021 Article in press: June 1, 2021 Published online: August 6, 2021 Processing time: 125 Days and 22.8 Hours
Abstract
BACKGROUND
Primary hepatic neuroendocrine tumors (PHNETs) are rare hepatic tumors. Their diagnosis, which is based on radiological findings, is difficult.
CASE SUMMARY
We present a case of PHNET in a 79-year-old man with no clinical symptoms. Computed tomography (CT) and 2-Deoxy-2-[fluorine-18] fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) were performed for further evaluation. A hypoattenuating mass with rim-like enhancement in segment 6 of the liver was detected on contrast-enhanced CT imaging. Increased uptake was also observed on 18F-FDG PET/CT. Histopathological and immunohistochemical examinations, which revealed a grade 2 neuroendocrine tumor (NET), confirmed the diagnosis.
CONCLUSION
Diagnosing PHNET is challenging, and must be distinguished from other liver tumors. Metastatic NETs should be excluded.
Core Tip: Primary hepatic neuroendocrine tumors (NETs) are rare hepatic tumors. The diagnosis of these tumors, based on radiological observations, is difficult, and requires distinguishing them from other liver tumors and excluding metastasized NETs. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is helpful when excluding extrahepatic diseases and evaluating the prognosis. Pathological diagnosis based on histological and immunohistochemical evaluation is regarded as the standard diagnosis. Complete surgical resection is the only curative option. For inoperable cases, transarterial chemoembolization, chemotherapy, and radiofrequency ablation are alternative treatment methods.
